anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
The invention, to be presented for use in hospitals and health institution, is a patient experience management system that measures performance by asking patients&#39; opinions on the services provided in the hospitals and health institution using thorough questionnaires and analyze the patients&#39; responses to score the performance, detect causes of performance alterations, and suggest solutions and prioritizing. This patient experience management system (1) has the following characteristics: using contacts of patient(s) (10) that are provided by hospitals and health institution (40), the patient(s) (10) are contacted and asked about their opinions on the provided services and treatments in the hospitals and health institution (40), the opinions of the patient(s) (10) are asked using thorough questionnaires (20). The responses of the patient(s) (10) on these questionnaires (20) questions are entered in a server (30) that has a built in Artificial Intelligence based matrix (31). The server (30) with its built in Artificial Intelligence based matrix (31) analyzes the responses and report the score, the Coefficient of Variation, the occurrence pattern, and trending. The server (30) with its built in Artificial Intelligence based matrix (31) then analyzes the score, the Coefficient of Variation, the occurrence pattern, and trending all together to report performance, detect causes of performance alterations, and suggest solutions and prioritizing. These results are then fed by the server (30) to the hospitals and health institution (40) on agreed intervals (real-time, weekly, monthly, etc.)
The invention comprises tetrahydro-isoquinoline derivatives of the formula &lt;FORM:0995369/C2/1&gt; wherein n stands for 1, 2 or 3, R1 is a halogen atom and R2 is a hydrogen atom or an alkyl group containing up to 4 carbon atoms, and the corresponding compounds in which the hydroxyl group in the 6- or 7-position is replaced by an alkoxy group containing at least 2 carbon atoms or an acyloxy group, and acid-addition salts thereof.  The compounds are prepared by reductively debenzylating, e.g. using hydrogen in the presence of a metal hydrogenation catalyst, a compound of the formula &lt;FORM:0995369/C2/2&gt; and, if desired, replacing the hydrogen atom of the hydroxyl group in the 6- or 7-position by an alkyl group containing at least 2 carbon atoms or an acyl group by etherification or esterification as the case may be, and also if desired, converting the product of any of the foregoing steps into an acid-addition salt. Pharmaceutical compositions for enteral and parenteral administration having analgesic, antitussive and antirheumatic activity comprise a compound of the invention together with a pharmaceutically acceptable carrier.  They may be formulated as tablets, dragees, suppositories, capsules, solutions, suspensions or emulsions.  Specification 995,370 is referred to.
The invention comprises (1) a process for preparing compounds of the formula &lt;FORM:0991933/C2/1&gt; (wherein each R is hydrogen or alkyl, R1 is a saturated or unsaturated aliphatic hydrocarbon radical, Q is methylene or ethylene, Y is hydroxymethylene, acyloxymethylene or a ketalized carbonyl group and the o-phenylene group is substituted by one or more hydroxy, acyloxy or alkoxy groups, at least one such group being present in the 3-position) by reducing, reducing and esterifying or ketalizing a compound of the above structure wherein Y is a carbonyl group; and (2) compounds of the above structure wherein R, R1, Q and Y are as defined above and the o-phenylene group is substituted in the 3-position by a hydroxy, acyloxy or alkoxy group. The reduction is preferably performed with a borohydride or with lithium aluminium hydride. Acylation may be effected with an organic acid, particularly a carboxylic acid, and ketalization with, for example, methanol or ethanol or a glycol. In the products, a 3-hydroxy group can be acylated.  Also, the products may be converted to 8-iso-steroids by hydrogenation, using a platinum catalyst to saturate both ethylenic linkages.  Diene ketone starting materials may be prepared in situ by the process described in Specification 991,592. Examples are given.
The present invention relates to a preparation method of medicine for treating fractures and soft tissue injury, particularly to a preparation method of a bone reunion tablet of standard medicine in traditional Chinese medicine historical preparations. In the preparation method, the bone reunion tablet is manufactured into a capsule preparation. Half liang of lizard added with fortune&#39;s drynaria rhizome and ningpo yam rhizome are decocted for three times with water. Decoction solutions are combined, and are concentrated into clear paste with the relative density of 1.15 to 1.20 after filtration. Surplus lizard is pulverized into fine powder for being added to the clear paste. The clear paste and the fine powder are packed to a capsule after even stirring, drying and pulverization. The bone reunion capsule prepared by the preparation method has the advantages of dosage reduction, disintegration time acceleration and easy absorption for a human body under the premise that the bone reunion capsule keeps the therapeutic effect of the original bone reunion tablet.
PURPOSE: To obtain a new condensed pyridazine compound useful for preventing and treating cardio-vascular insufficiency, having excellent inhibitory action on CGMP-PDE(cyclic GMP phosphodiesterase), high watersolubility, excellent absorption in body and low toxicity. CONSTITUTION: This condensed pyridazine-based compound is shown by formula I (ring C is a 5- to 6-membered ring which may contain a hetero atom; (n) is an integer of 0 or 1-4; R&lt;1&gt; is a halogen, nitro, cyano, etc.,; A is H, a halogen, an aryl, etc.; X is a group of the formula N, etc.; Y is group of the formula CO, etc.; an alternate long and short dash line is a double bond or a single bond with the proviso that a case where (n) is 0 is omitted when the ring C is a benzene ring) or its pharmacologically permissible salt. The most preferable example is a compound of formula II. The compound of formula I, for example, is obtained by halogenating a 1,4-phthalazinedione derivative.
PURPOSE:To provide the titled suppository containing nifedipin as a principal drug and compounded with a base and a polymer. CONSTITUTION:A long-active nifedipin suppository is produced by using &lt;=5pts. wt., preferably 0.5-1.5pts.wt. of nifedipin as a principal drug component and compounding the component with 3-20pts. of a polymer (e.g. copolymer of ethyl methacrylate and chloromethylammonium ethyl methacrylate) and a proper amount of a base (e.g. polyethlyene glycol 400, polyethylene glycol 6,000, etc.) to obtain 100pts.wt. of the product. It can be absorbed rapidly through the rectum and the concentration of nifedipin in blood can be maintained for a long period. Accordingly, the drug action can be continued with little influences to food, symptoms, posture, psychological stress, etc.
The invention relates to a medicinal wine capable of warming kidney and invigorating yang and a preparation method thereof. The medicinal wine is prepared from the following raw materials in parts by weight: 30-35g of Chonemorpha macrophylla, 25-30g of Morinda officinalis, 15-20g of wolf&#39;s bane, 30-40g of cornel, 16-20g of radix rehmanniae, 10-20g of schisandra fruit, 10-20g of hemlock parsley, 40-45g of acanthopanax bark, 10-15g of ginseng, 40-43g of broomrape, 30-40g of radix astragali, 10-20g of cinnamon, 30-32g of radix sileris, 15-18g of pepper, 20-25g of ginger, 15-20g of magnet, 10-12g of oriental wormwood and 3500-4000g of 50 %vol white wine. The Chinese herbal medicines used by the medicinal wine are abundant in sources, and are common and cheap. The preparation method is scientific, simple and practical. The medicinal wine is nontoxic, is convenient to take, and can regulate the function of the human body. The medicinal wine prepared from the Chinese herbal medicines has the effects of warming the kidney, invigorating yang and strengthening the bones and muscles.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an aripiprazole anhydrous crystal scarcely converting into a hydrate even when a pharmaceutical preparation containing the aripiprazole anhydrous crystal is preserved over a long period without substantially lowering eluting properties.  &lt;P&gt;SOLUTION: This aripiprazole anhydrous crystal exhibits the same 1H-NMR spectrum as that shown in, e.g. Fig. 2 (refer to the specification), the same powder X-ray diffraction spectrum as that shown in Fig. 3 (refer to the specification) and the same IR (KBr) spectrum as that shown in Fig. 4 (refer to the specification). The aripiprazole anhydrous crystal is low hygroscopic and scarcely converts into the hydrate even when preserved over a long period.  &lt;P&gt;COPYRIGHT: (C)2003,JPO
The present invention discloses a water and oil soluble O-chitosan derivative, the preparation thereof and the application thereof, which belongs to the preparation and application technology of chitosan derivatives. The water and oil soluble O-chitosan derivative is a derivative substituent for ring carbon 6-OH of chitosan and is synthetized by using chitosan as a raw material. The water and oil soluble O-chitosan derivative comprises O-ethylamine hydroxyethyl chitosa, O-2&#39;-hydroxypropyl-N and N-octadecy l dimethyl ammonium chloride chitosan. The preparation of the water and oil soluble O-chitosan derivative comprises: reaction products of N-phthaloyl chitosan, chloroethanol and aminoethyl chloride hydrochloride react with reaction products of N-octadecy l dimethyl ammonium chloride chitosan and epoxy chloropropane in a medium of isopropyl alcohol so as to obtain the water and oil soluble O-chitosan derivative. When animal feed in which 2.5 to 7.5 wt% of the water and oil soluble O-chitosan derivative is added is used for feeding rats, the water and oil soluble O-chitosan derivative has obvious function for treating and preventing the obesity of the rats. Weight losing products of the chitosan of the present invention have the advantages of naturalness, no poison, obvious weight losing effect, no side effect to human body, etc. The oil soluble O-chitosan derivative not only can be used for treating obesity, but also can be used for preventing obesity.
PURPOSE: A system for transmitting a medical prescription and a method thereof are provided to decrease a waiting time by transmitting a medical prescription to a drugstore which is used by a medical consumer most conveniently in real time using a mobile telephone network or the Internet. CONSTITUTION: If a medical consumer visits a hospital for receiving a medical treatment, the hospital inputs a prescription to a smart card of the medical consumer through a smart card terminal after a medical treatment(410). The medical consumer performs a log-in process to a prescription transmission server using the Internet or a mobile communication network. The medical consumer transmits the prescription to the prescription transmission server. The prescription transmission server judges whether the consumer wishes to use one&#39;s favorite drugstore(430). If the consumer does not wish to use one&#39;s favorite drugstore, a proper drugstore list is prepared and suggested to the consumer(432). The consumer selects a wanted drugstore out of the list(434). The prescription transmission server judges whether the selected drugstore is open(440). If the selected drugstore is open, a code prescription is transmitted to the drugstore(450). The prescription transmission server judges whether a response related to a compounding is existed from the drugstore(455). If a response is existed, it is judged whether the consumer wishes to receive the compounded drug through a delivery(460). If the consumer does not wish to receive the compounded drug through a delivery, the prescription transmission server transmits a process result to the consumer(470).
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain an extract of spore of Ganoderma lucidum which exhibits various pharmacological actions such as anti-cancer action, etc., and a preparation of spore of Ganoderma lucidum.  &lt;P&gt;SOLUTION: The extract of spore of Ganoderma lucidum is obtained by alcohol extraction of spore of Ganoderma lucidum with 80-100% hydrous methanol or 60-100% hydrous ethanol. The preparation of Ganoderma lucidum comprises an extract of spore of Ganoderma lucidum. The figure (a) is a bar chart indicating the examined result of a relation between a methanol (MeOH) concentration in an extraction solvent used in the alcohol extraction and anticancer effect on a human leukemic cell strain (HL60 cell). The figure (b) is similarly a bar chart indicating the examined result of a relation between an ethanol (EtOH) concentration and anticancer effect.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
The invention discloses a device for quickly predicting liver cancer risk level, which mainly comprises a data acquisition module, a database, a data processing module and a risk evaluation module. The data acquisition module acquires basic data of a tester and stores the basic data of the tester into a preliminary data matrix P of the database. And the data processing module calls and processes the preliminary data matrix P in the database to obtain a sample data matrix P &#39;and inputs the sample data matrix P&#39; into the risk assessment module. The risk evaluation module stores a liver cancer risk evaluation model. And the liver cancer risk evaluation model processes the sample data matrix P&#39; and outputs a risk evaluation result y. The invention ensures the reliability of liver cancer risk prediction.
The present invention concerns a polynucleotide construct encoding a mini-receptor of SORLA. The present invention further concerns a vector, a cell and/or a composition comprising said polynucleotide construct. The present invention further concerns a polypeptide representing a mini-receptor of SORLA. The present invention further concerns said vector, said cell and/or said composition comprising said polynucleotide construct, for use in medicine. The present invention further concerns said vector, said cell and/or said composition comprising said polynucleotide construct, for use in treatment, prevention and/or alleviation of Alzheimer&#39;s Disease or a disease or disorder associated with Alzheimer&#39;s Disease. The present invention further concerns a method of treating Alzheimer&#39;s Disease or a disease or disorder associated with Alzheimer&#39;s Disease. The present invention further concerns a method of increasing sAPP? in a cell. The present invention further concerns a method of decreasing A?38, A?40, and/or A?42 in a cell.
PURPOSE:To provide a germanium-containing medicinal liquid containing an aqueous solution containing a specific amount of germanium as a main agent and exhibiting remarkable remedying effect to athlete&#39;s foot, skin-beautifying effect, hair tonic effect, body warming effect, etc. CONSTITUTION:A germanium-containing medicinal liquid is produced by using an aqueous solution containing 200-4,000ppm of germanium (in terms of element) as a main agent. The germanium-containing medicinal liquid has excellent remedying effect to athlete&#39;s food, skin activation effect, hair tonic effect, body- warming effect, blood flow accelerating effect, etc. Since germanium is unreactive with ordinary compounds, it can be used in combination with other liquid cosmetic (e.g. milky lotion, hair dressing, etc.). It is useful also as a base aqueous solution for water-based ointment.
The invention discloses a ferulic acid and phospholipid complex and application thereof to preparation of skin-whitening cosmetics. The ferulic acid and phospholipid complex is obtained after ferulic acid and phospholipid are heated, stirred and compounded in a non-protonic solvent and the non-protonic solvent is removed. The invention also provides the skin-whitening cosmetics containing the ferulic acid and phospholipid complex. The cosmetics include skin oil, emulsion and cream with the skin whitening effect. According to the ferulic acid and phospholipid complex, ferulic acid and phospholipid are compounded, so that physicochemical properties of ferulic acid are changed, fat solubility, stability and water dispersibility of the complex are enhanced, the transmembrane transport performance of the complex is improved, and then the bioavailability of the complex is increased. After 30 female volunteers at the age of 25-45 use the skin-whitening and skin-caring emulsion containing the ferulic acid and phospholipid complex for 30 days, the melanin content of their faces is lowered obviously, the brightness of their skin is increased, the MI value, L* value and ITA degree value of their skin are remarkably different from original values (P&lt;0.05), and it is indicated that the skin-whitening emulsion has a good human body skin whitening effect.
PURPOSE:To provide the subject safe cosmetic stable for a long period of time, excellent in the absorbability for the active ingredient and the sustainability of its effect. CONSTITUTION:The objective cosmetic formulated with a liposome with the constituent being dialkyl-type phospholipid and/or its derivative of the formula (R&lt;1&gt;-R&lt;3&gt; are each H or lower alkyl), a form of old bacterial lipids, capable of mass synthesis and industrial production (e.g. 1,2-di-O-phytanyl-glycero- phosphocholine; where, R&lt;1&gt;=R&lt;2&gt;=R&lt;3&gt;=CH3). This liposome is excellent in both thermal stability and preservability compared with conventional liposomes consisting of diacyl-type phospholipids having been generally used, being also stable to the change in pH and osmotic pressure and to physiologically active substances, etc. Besides, this liposome, like conventional ones, has percutaneous absorption effect and such effect&#39;s sustainability, and the phospholipid as the constituent is also high in biocompatibility. For the present liposome, any substance having effects as cosmetics, such as humectant effect, skin whitening effect, aging-preventive effect, dermal cell-activating effect, or ultraviolet light absorption or screening effect, can be used.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a tablet which can include a soft substance such as fluid and an elastic or plastic solid that could not be included in the tablet.  &lt;P&gt;SOLUTION: This tablet having a soft substance therein is characterized by having the soft substance in the ultrasonic wave oscillation compression molded article of a mixture comprising the powder of a raw material and a polymer binder which is solid at ordinary temperature and has a melting point of ≤100°C. The soft substance comprises, for example, one of (i) an elastic or thermoplastic deformable solid, (ii) a fluid, and (iii) a content-sealed capsule. The tablet 1 is preferably obtained by burying the soft substance in the mixture and compressing the product in the buried state, while giving ultrasonic wave oscillations. The mixture preferably contains the polymer binder which is solid at the ordinary temperature and has the melting point of ≤100°C.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
The invention relates to a drug delivery system comprising an oil-in-water microemulsion to improve the solubility and bioavailability of lipophilic active ingredient. The invention also provides a pharmaceutical composition containing magnolol microemulsion, and the use of magnolol and its micro-emulsion to prepare a drug for treating apoplexy. The drug delivery system comprises an active ingredient and a carrier system for forming an oil-in-water microemulsion. The carrier system includes water, oil and emulsifier, wherein the weight percentage of water is 5% to 60%, the weight percentage of oil is 5% to 80% and the weight percentage of emulsifier is 15% to 90% based on the total weight of the carrier system. The oil contains fatty acid oil and the emulsifier contains a surfactant and a cosurfactant, wherein the surfactant is a nonionic surfactant. The oil further contains oleic acid, triglyceride, olive oil, glycerol, &lt;alpha&gt;-linolenic acid (ALA), heneicosapentaenoic acid (HPA), eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), eicosatetraenoic acid (ETA), eicosatrienoic acid (ETE), linoleic acid, &lt;gamma&gt;-linolenic acid (GLA), arachidonic acid (AA) or any combination thereof. The surfactant includes Tween, and/or the co-surfactant includes propylene glycol, polyethylene glycol (PEG), diethylene glycol monoethyl ether, labrasol, ethoxylated hydrogenated castor oil, polyvinyl alcohol (PVA), or any combination thereof. The emulsifier contains Tween 80, 1,2-propylene glycol (1,2-PG), and polyethylene glycol 400 (PEG 400), wherein the content of Tween 80 is 5% to 60%, the content of 1,2-propylene glycol is 5% to 60% and the content of polyethylene glycol 400 is 5% to 60% based on the total amount of emulsifier. The active ingredient comprises any one or a combination of magnolol, curcumin or a medicinal salt thereof. The diameter of the droplets in the microemulsion ranges from 50 nm to 2500 nm. The viscosity of the microemulsion is 15 to 200 centipoise (cP). The drug loading for the active ingredient of the microemulsion is at least 10 mg/ml.
PURPOSE:To retain the smell of perfume and eliminate the powder smoke smell by compounding a powder of 5-100 micron, which contains the perfume. CONSTITUTION:The powder of 5-100 micron containing the perfume is compounded. The powder having the grain size of 5-100 micron has a large surface area and good volatility whereby the powder effects masking of the powder smoke small immediately after the explosion by evaporating the perfume. The perfurming rate of the powder, containing the perfume is preferably 10-50wt.% with respect to the powder while the blending amount of the powder to the cracker is preferably 0.1-1.0g. Perfume having the smell of flowers such as rose, jasmine, lilly of the valley and the like, citurus fruits perfume such as lemon, oranges and the like, perfume such as &#39;CHYPRE(R)&#39;, &#39;CHANEL(R)&#39;, &#39;MITSUKO(R)&#39; and the like are employed for the perfume while inorganic powder, such as zinc oxide, titanium dioxide, talk, mica, sericite, kaolin, micaceous titanium and the like, are employed as the powder. According to this method, fragrant odor can be given in a room and the like and the powder smoke smell can be eliminated.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a new beauty agent raw material for preventing or retarding the appearance of skin ageing symptom, or weakening an effect thereof.  &lt;P&gt;SOLUTION: The invention relates to the use of a plant extract as a beauty agent. The extract is obtained as a beauty-activating agent from a plant belonging to the genus Citrus or from a hybrid obtained by the hybridization of plant species whose at least one belongs to the genus Citrus. The extract is obtained from a plant belonging the genus ×Citrofortunella. Especially, the extract of calamondin (×Citrofortunella microcarpa) is suitable. The extract can prevent or retard the appearance of skin ageing symptoms, weaken the effect thereof, and/or improve or recover the gloss or bright glow of the skin.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
The present invention relates to the compound represented by formula (I) (wherein R 1 and R 2 is hydrogen atom, C1-8 alkyl etc.; R 3 is C1-8 alkyl which may be substituted with 1 to 3 halogen atom(s), phenyl; R 4 is hydrogen atom etc. ; R 5 and R 6 is hydrogen atom, CI-8 alkyl etc.; X is sulfur atom or oxygen atom etc.; ringA is cyclic group which may have a substituent(s).), or a salt thereof Toxicity of the compound represented by formula (I) is very low, and it is safe enough to use as a pharmaceutical agent and since it has PPAR &#39; agonistic activity, it is useful as preventive and/or therapeutic agent for glucose lipid metabolic disorder, hypertension, circulatory diseases etc.